BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu W, Lettiere D, Tse S, Johnson TR, Biddle KE, Thibault S, Palazzi X, Chen J, Pithavala YK, Finkelstein M. Liver Toxicity Observed With Lorlatinib When Combined With Strong CYP3A Inducers: Evaluation of Cynomolgus Monkey as a Nonclinical Model for Assessing the Mechanism of Combinational Toxicity. Toxicol Sci 2021;182:183-94. [PMID: 34021354 DOI: 10.1093/toxsci/kfab056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Verdura S, Encinar JA, Fernández-Arroyo S, Joven J, Cuyàs E, Bosch-Barrera J, Menendez JA. Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells. Int J Mol Sci 2022;23. [PMID: 36077379 DOI: 10.3390/ijms23179986] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Baba K, Goto Y. Lorlatinib as a treatment for ALK-positive lung cancer. Future Oncol 2022. [PMID: 35787143 DOI: 10.2217/fon-2022-0184] [Reference Citation Analysis]